Lexicon to present at Citi Biopharma Back to School investor conferencePUBT·Sep 1 at 08:09 PMLXRX-0.88%
Lexicon Pharmaceuticals to Participate at Three Upcoming Investor ConferencesUnusual Whales·Sep 1 at 08:06 PMLXRX-0.88%
Lexicon post hoc SOLOIST-WHF analysis shows sotagliflozin benefit holds across baseline blood pressure levelsPUBT·Aug 31 at 12:32 PMLXRX-0.88%
Niche Equities Show Divergent Q2 2026 Results Amid Market ShiftsGlobal Report·Aug 25 at 10:12 AMWU-0.97%OCUL0.00%
10:32 ETHypertrophic Cardiomyopathy Market Set for Transformation Over the Next Decade with the Emergence of Targeted Cardiac Therapies Beyond Conventional Beta-blockers, Calcium Channel Blockers, and Antiarrhythmic Agents | DelveInsightprnewswire·Aug 17 at 02:33 PMLXRX-0.88%CYTK-1.66%
Rockwell Raises Guidance as AES Advances Buyout in Q2 ReshuffleGlobal Report·Aug 11 at 09:43 AMLXRX-0.88%DOMH-1.41%
The 2026 Divergence: Cautious Consumers and Aggressive Industrial Infrastructure BetsGlobal Report·Aug 9 at 09:12 AMMPLX+0.56%WDCVV0.00%
Wall Street's Leftover Drawer Is a Bizarre Mix, and Here's WhyGlobal Report·Aug 8 at 09:20 AMHKIT+1.00%O.PR0.00%
Divergent Q2 Trajectories Highlight Strategic Shifts Across 10 US EquitiesGlobal Report·Aug 7 at 09:18 AMLAB+1.72%OILCF0.00%
Lexicon Q2 FY26 net loss widens to $31.8 million; revenue drops to $0.7 millionPUBT·Aug 6 at 11:36 AMLXRX-0.88%
Lexicon Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q2 financial results.benzinga_article·Aug 6 at 12:46 PMLXRX-0.88%
